Hims & Hers Health, Inc. (HIMS)
Automate Your Wheel Strategy on HIMS
With Tiblio's Option Bot, you can configure your own wheel strategy including HIMS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol HIMS
- Rev/Share 8.9741
- Book/Share 2.5079
- PB 18.8129
- Debt/Equity 1.856
- CurrentRatio 4.9795
- ROIC 0.1086
- MktCap 10268349560.0
- FreeCF/Share 0.5326
- PFCF 85.9233
- PE 54.6786
- Debt/Assets 0.5562
- DivYield 0
- ROE 0.3817
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | HIMS | Needham | Buy | Hold | -- | -- | June 23, 2025 |
| Reiterated | HIMS | Needham | -- | Buy | $61 | $65 | June 4, 2025 |
| Downgrade | HIMS | TD Cowen | Buy | Hold | -- | $30 | April 29, 2025 |
| Downgrade | HIMS | Morgan Stanley | Overweight | Equal Weight | $42 | $60 | Feb. 18, 2025 |
| Downgrade | HIMS | Citigroup | Neutral | Sell | $24 | $25 | Jan. 10, 2025 |
| Initiation | HIMS | BTIG Research | -- | Buy | -- | $35 | Jan. 7, 2025 |
| Initiation | HIMS | Morgan Stanley | -- | Overweight | -- | $42 | Dec. 17, 2024 |
| Initiation | HIMS | Needham | -- | Buy | -- | $24 | Aug. 22, 2024 |
News
Hims & Hers Can Still Thrive Without GLP-1s
Published: July 01, 2025 by: Seeking Alpha
Sentiment: Positive
Hims & Hers has achieved explosive revenue and subscriber growth, driven by its direct-to-consumer telehealth model and expanding product lines. The recent termination of the Novo Nordisk partnership and regulatory scrutiny on GLP-1 drugs pose significant long-term growth risks. Despite Amazon's entry into telehealth, Hims maintains a strong niche with high subscriber growth and improved gross margins.
Read More
Deadline Alert: Hims & Hers Health, Inc. (HIMS) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Published: July 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, July 01, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming August 25, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) securities between April 29, 2025 and June 23, 2025, inclusive (the “Class Period”).
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Hims & Hers Health, Inc. of Class Action Lawsuit and Upcoming Deadlines - HIMS
Published: July 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”) (NYSE: HIMS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Read More
HIMS Investor Alert: Contact Kessler Topaz Meltzer & Check, LLP About the Securities Fraud Class Action Lawsuit Filed
Published: June 30, 2025 by: PRNewsWire
Sentiment: Neutral
RADNOR, Pa. , June 30, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that securities class action lawsuits have been filed in the United States District Court for the Northern District of California against Hims & Hers Health, Inc. ("Hims & Hers") (NYSE: HIMS) on behalf of those who purchased or otherwise acquired Hims & Hers securities between April 29, 2025, and June 23, 2025, inclusive (the "Class Period").
Read More
Hims & Hers Health, Inc. (HIMS) Faces Securities Class Actions After Novo Nordisk Cancels Partnership Over “Deceptive” Marketing of Wegovy®– Hagens Berman
Published: June 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, June 30, 2025 (GLOBE NEWSWIRE) -- On June 25, 2025, two securities class action lawsuits were filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the company's executives. Sookdeo v.
Read More
HIMS & HERS HEALTH, INC. (NYSE: HIMS) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Hims & Hers Health, Inc. Investors of Upcoming Deadline
Published: June 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join This Class Action Lawsuit?
Read More
Hims & Hers vs. LifeMD: Which Telehealth Stock Has More Upside?
Published: June 30, 2025 by: Zacks Investment Research
Sentiment: Positive
HIMS and LFMD are surging in the telehealth race, but which one has stronger earnings growth and expansion momentum? Let's see.
Read More
Hims & Hers: You Are Missing The Big Picture
Published: June 30, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk just killed the deal. But Hims might come out even stronger. Here's why the market got it wrong. GLP-1s are just the tip of the iceberg. Hims is quietly positioning itself as the gateway to the next wave of medical breakthroughs. The stock plunged more than 40%, but our DCF shows it could be worth $70-plus. This might be the best buying opportunity yet.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Hims & Hers Health, Inc. of Class Action Lawsuit and Upcoming Deadlines - HIMS
Published: June 27, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , June 27, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
Deadline Alert: Hims & Hers Health, Inc. (HIMS) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Published: June 27, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP reminds investors of the upcoming August 25, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) securities between April 29, 2025 and June 22, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR HIMS INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO.
Read More
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – HIMS
Published: June 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 27, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of Hims & Hers Health, Inc. (NYSE: HIMS) between April 29, 2025 and June 23, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 25, 2025.
Read More
HIMZ: Buy For Short-Term Gains On Hims & Hers Health, But Be Wary Of The Risks
Published: June 27, 2025 by: Seeking Alpha
Sentiment: Neutral
HIMZ offers 2x leveraged exposure to HIMS, ideal for high-risk, short-term traders seeking amplified volatility, not long-term investors. Recent HIMS volatility, including the Novo Nordisk partnership fallout, creates attractive trading opportunities for nimble investors using HIMZ. HIMS continues to innovate and expand, targeting new markets and launching products, leading to strong growth potential and future catalysts.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Hims & Hers Health, Inc. - HIMS
Published: June 27, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , June 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Class Action Announcement for Hims & Hers Health, Inc. (HIMS): Kessler Topaz Meltzer & Check, LLP
Published: June 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
RADNOR, Pa., June 27, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that securities class action lawsuits have been filed in the United States District Court for the Northern District of California against Hims & Hers Health, Inc. (“Hims & Hers”) (NYSE: HIMS) on behalf of those who purchased or otherwise acquired Hims & Hers securities between April 29, 2025, and June 23, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is August 25, 2025.
Read More
Health & Fitness Stocks to Buy as the Wellness Trend Grows
Published: June 27, 2025 by: Zacks Investment Research
Sentiment: Positive
SFM, BODI, and HIMS are capitalizing on the booming wellness market with digital tools, nutrition, and holistic health solutions.
Read More
Hims & Hers Health, Inc. (HIMS) Faces Securities Class Actions After Novo Nordisk Cancels Partnership Over "Deceptive" Marketing of Wegovy®- Hagens Berman
Published: June 27, 2025 by: PRNewsWire
Sentiment: Neutral
SAN FRANCISCO , June 27, 2025 /PRNewswire/ -- On June 25, 2025, two securities class action lawsuits were filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the company's executives. Sookdeo v.
Read More
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Hims & Hers Health, Inc. (HIMS)
Published: June 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all persons or entities who purchased or otherwise acquired Hims & Hers Health, Inc. (“Hims and Hers” or the “Company”) (NYSE: HIMS) securities between April 29, 2025 and June 23, 2025, both dates inclusive (the “Class Period”).
Read More
Hims & Hers Health, Inc. (HIMS) Faces Securities Class Actions After Novo Nordisk Cancels Partnership Over “Deceptive” Marketing of Wegovy– Hagens Berman
Published: June 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, June 26, 2025 (GLOBE NEWSWIRE) -- On June 25, 2025, two securities class action lawsuits were filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the company's executives. Sookdeo v.
Read More
HIMS Investors with Losses in Excess of $100K Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit
Published: June 26, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , June 26, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of Hims & Hers Health, Inc. (NYSE: HIMS) between April 29, 2025 and June 23, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.
Read More
Stocks on the Move: Hims & Hers Health and JetBlue
Published: June 26, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee discuss their strategy on some stocks on the move today.
Read More
NYSE: HIMS: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Class Action Lawsuit Against Hims & Hers Health, Inc. (HIMS)
Published: June 26, 2025 by: Business Wire
Sentiment: Neutral
RADNOR, Pa.--(BUSINESS WIRE)-- #classaction--The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that securities class action lawsuits have been filed against Hims & Hers Health, Inc. (“Hims & Hers”) (NYSE: HIMS) on behalf of those who purchased or otherwise acquired Hims & Hers securities between April 29, 2025, and June 23, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is August 25, 2025. CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP: If y.
Read More
HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: June 26, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)---- $HIMS--HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit with the Schall Law Firm.
Read More
Rosen Law Firm Urges Hims & Hers Health, Inc. (NYSE: HIMS) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
Published: June 26, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of common stock of Hims & Hers Health, Inc. (NYSE: HIMS) between April 29, 2025 and June 23, 2025. Hims describes itself as a “U.S.-based telehealth company that offers online access to health consultations and treatments.” For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Ro.
Read More
Hims & Hers Health (HIMS) Loses 22.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Published: June 26, 2025 by: Zacks Investment Research
Sentiment: Negative
The heavy selling pressure might have exhausted for Hims & Hers Health (HIMS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Read More
Hims Won't Back Down From Selling Cheap Weight-Loss Shots
Published: June 26, 2025 by: Bloomberg Markets and Finance
Sentiment: Negative
Hims & Hers Health CEO Andrew Dudum said the company will continue to sell cheap weight-loss shots despite Novo Nordisk A/S ending their distribution partnership over "deceptive marketing" practices. Sam Fazeli has more on "Bloomberg Open Interest.
Read More
Hims & Hers Health, Inc. (HIMS) Shares Crash After Novo Nordisk Cancels Partnership Over "Deceptive" Marketing of Wegovy, Faces Investor Scrutiny- Hagens Berman
Published: June 25, 2025 by: PRNewsWire
Sentiment: Neutral
SAN FRANCISCO , June 25, 2025 /PRNewswire/ -- On June 23, 2025 investors in Hims & Hers Health, Inc. (NYSE: HIMS) saw the price of their shares crash over 30% after Novo Nordisk announced that it terminated its collaboration with the telehealth company due to concerns about Hims & Hers' sales and "deceptive" marketing of the weight loss drug Wegovy®. This news has prompted national shareholders rights firm Hagens Berman to open an investigation into possible violations of the securities laws.
Read More
HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law Firm
Published: June 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, June 25, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Hims & Hers Health, Inc. (“Hims & Hers” or “the Company”) (NYSE: HIMS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Read More
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
Published: June 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Hims & Hers Strengthens Its Footprint in Consumer-Driven Obesity Care
Published: June 24, 2025 by: Zacks Investment Research
Sentiment: Positive
HIMS expands its weight loss platform with a bundled Wegovy program and tech-driven obesity care solutions.
Read More
Hims & Hers: The Novo Nordisk Breakup Changes Nothing
Published: June 24, 2025 by: Seeking Alpha
Sentiment: Positive
The Novo Nordisk partnership ending does not alter my long-term bullish thesis on HIMS; the company is much more than just a GLP-1 play. HIMS' core value lies in its broad treatment offerings and disruptive model, not in partnerships with big pharma like NVO. Legal risks remain, but I believe HIMS is well-positioned to defend itself, and no legal action has been initiated by NVO yet.
Read More
About Hims & Hers Health, Inc. (HIMS)
- IPO Date 2019-09-13
- Website https://www.forhims.com
- Industry Household & Personal Products
- CEO Andrew Dudum
- Employees 1637